Aerska raised $39M in a Series A round announced on February 9, 2026. Aerska has developed an antibody-oligonucleotide conjugate (AOC) platform that uses “brain shuttles” to help deliver RNAi directly to the brain, allowing for better uptake by neurons and lasting gene knockdown.
Aerska has developed an antibody-oligonucleotide conjugate (AOC) platform that uses “brain shuttles” to help deliver RNAi directly to the brain, allowing for better uptake by neurons and lasting gene knockdown.
Aerska, based in Dublin, Ireland, announced $39M in Series A financing on February 9, 2026.
Participants include Age1, EQT Dementia Fund, Iaso Ventures.
the company behind NEUROMARK, a minimally invasive solution to treat chronic rhinitis.
a TechBio company focused on transforming clinical trials through artificial intelligence.
a platform that enables employees to build compliant enterprise software without writing code.